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Abstract
Artificial transcription activator-like (TAL) effector-based activators (TALE activators) have
broad utility but previous studies suggest that these monomeric proteins often possess low
activities. Here we demonstrate that TALE activators can robustly function individually or in
synergistic combinations to increase expression of endogenous human genes over wide dynamic
ranges. These findings will encourage applications of TALE activators for research and therapy
and guide design of novel monomeric TAL effector-based fusion proteins.
Rapid advances in Xanthomonas-derived transcription activator-like (TAL) effector
technology have enabled any researcher to construct customizable DNA-binding domains
with broad potential uses for targeted alteration of gene sequence or expression. Highly
conserved 33–35 amino acid TAL effector repeat domains each bind one nucleotide of DNA
with specificity dictated by two hypervariable residues.1 This one-to-one code enables the
design of proteins with desired DNA-binding specificities by simply joining TAL effector
repeats into an array. Recently, considerable effort has been focused on dimeric TAL
effector nucleases (TALENs), artificial proteins composed of customized TAL effector
repeats fused to a nuclease domain, which enable targeted modification of endogenous genes
in a variety of organisms and cell types.2 Engineered TAL effectors have also been fused to
heterologous transcriptional activation domains to construct artificial monomeric TAL
effector activators (TALE activators) (Supplementary Fig. 1).3–11 However, in contrast to
the high efficiencies reported for dimeric TALENs, the activities of monomeric TALE
activators reported thus far have often been disappointingly modest at best in their abilities
to increase target gene expression. For example, 22 of 26 published TALE activators (for
which quantitative information is available)3–6, 8, 9 failed to induce target endogenous gene
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expression by five-fold or more (Supplementary Table 1). The use of multiple different
architectures makes it difficult to ascertain what parameters may or may not influence the
activities of the TALE activators tested in these previous studies (Supplementary Table 1).
Here we leveraged our recently developed Fast Ligation-based Automatable Solid-phase
High-throughput (FLASH) assembly method12 to systematically test the activities of TALE
activators. In initial experiments, we constructed a large series of TALE activators
composed of variable numbers of TAL effector repeats and tested their abilities to stimulate
expression of the endogenous human VEGF-A gene. We targeted nine regions that all lie
within a DNase I hyper-sensitive site (HSS) located ~500 bp downstream of the VEGF-A
transcription startpoint (Fig. 1a) because previously published work with artificial zinc
finger-based transcriptional activators has shown that targeting sequences in HSSs greatly
enhances success rates.13 We constructed sets of six variable-length TALE activators
(composed of 14.5, 16.5, 18.5, 20.5, 22.5, or 24.5 TAL effector repeats) for each of the nine
target regions. All 54 proteins were built on a common architecture similar to one previously
described3 but that harbors a VP64 (instead of a VP16) activation domain (Methods and
Supplementary Figure 1). Strikingly, we found that 53 of these 54 TALE activators induced
significant increases in VEGF-A protein expression ranging from 5.3- to 114-fold (average
of 44.3-fold activation) (Fig. 1b) and that these activities do not appear to depend on which
strand of DNA is bound. We do not know precisely why we observed variability in the range
of fold-activations but possibilities include variable protein expression levels or differences
in the DNA-binding activities of the arrays. Regardless of mechanism, our results suggest
that TALE activators can function efficiently when they are targeted to a DNase I HSS.
To further test the robustness of TALE activators, we built proteins targeted to six additional
sites in the human VEGF-A promoter, five sites in the human NTF3 promoter, and five sites
in the microRNA miR-302/367 cluster promoter. All of these TALE activators were
composed of 16.5 or 17.5 TAL effector repeats and were targeted to sites within DNase I
HSSs (Supplementary Fig. 2 and Methods). Notably, all six TALE activators targeted to
VEGF-A and four of five activators targeted to the miR-302/367 cluster induced significant
increases of target gene expression in human HEK293 and primary BJ fibroblasts,
respectively (Fig. 2a and b). Because NTF3 mRNA is expressed at an essentially
undetectable level in the HEK293 cells used for our experiments, we were unable to
quantify fold-activation values for proteins targeted to this gene, but all five TALE
activators significantly increased expression of NTF3 relative to a GAPDH control (Fig. 2c).
Overall, 15 of these 16 TALE activators (~94%) induced significant increases in expression
of their endogenous gene targets (Fig. 2a–c).
We next explored whether replacing the VP64 domain in our TALE activators with an NF-
KB p65 domain would lead to consistently higher or lower levels of target gene expression.
For the 15 target sites for which we obtained active TALE activators, we found that the
mean fold-activation induced was lower with the NF-KB p65 TALE activators than with
their matched VP64 counterparts (Fig. 2a–c). We conclude that substitution with an NF-KB
p65 domain can provide a general approach for reducing the fold-activation induced by
TALE activators bearing a VP64 domain.
Because we were able to generate more than one active TALE activator for each target gene,
we also sought to test whether multiple proteins working simultaneously on a single
promoter could induce even greater levels of fold-activation. Naturally occurring
transcriptional activators can exhibit synergy – that is, the fold-activation observed in the
presence of multiple proteins is higher than the additive effects of the individual proteins.14
Activator synergy enables both combinatorial and graded control of transcription in
eukaryotes. We tested combinations of five VP64 or p65 TALE activators for their abilities
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to activate the miR-302/267 cluster or the NTF3 gene. Despite the fact that each TALE-
activator plasmid was present at one-fifth the level used when tested individually, we found
that multiple proteins induced substantially elevated target gene expression (Fig. 2bc).
Synergistic activation was observed with VP64 and p65 activators on the miR-302/367
cluster (Fig. 2b) and with p65 activators on the NTF3 gene (Fig. 2c). We also tested
combinations of six VP64 or p65 TALE activators for their abilities to activate the VEGF-A
gene but did not observe synergistic increases in expression (data not shown). We
hypothesized that the lack of observed synergy might be due to the different amounts of
TALE activator-encoding plasmids used in the individual and combination experiments.
Consistent with this, we found that both the VP64 and p65 TALE activators could mediate
synergistic increases in VEGF-A expression under conditions where the same amounts of
activator plasmids were used when tested individually or in combinations (Fig. 2d). We
conclude that both VP64 and p65 TALE activators can function synergistically to induce
even higher levels of endogenous gene expression than can be achieved using individual
activators.
Our ability to robustly construct highly active TALE activators contrasts with the collective
results of previous studies that described proteins with often much lower activities on
endogenous gene targets. We found that 62 of 65 (~95%) VP64 TALE activators (for which
we could calculate fold-activation values) increased expression of their target gene by five-
fold or more. Potential explanations for our higher success rate include our targeting of
DNase I HSSs or the sequence architecture of the TALE DNA-binding domains used
(Supplementary Discussion). Our findings also expand the types of genes and the range of
DNA sequences that can be targeted by TALE activators. To our knowledge, our results
provide the first demonstration that it is possible to activate a non-coding gene, thereby
broadening the range of potential targets for TALE activators. In addition, analysis of our
data suggests that there are no significant limitations in the range of sequences we can
successfully target (Supplementary Discussion and Supplementary Table 2). Taken together,
our results provide strong experimental support for the idea that TALE activators can be
used to control the expression of essentially any gene.
We have shown that TALE activators can be used to regulate target genes across a wide
dynamic range of expression, an important capability that will enable a broader range of
applications for this technology. Our studies suggest multiple potential approaches that
might be used to fine-tune the level of gene expression induced by TALE activators
(Supplementary Discussion). The finding that TALE activators can synergistically activate
transcription further broadens the range of gene expression changes that can be achieved
with this platform and raises the exciting possibility that target genes might be made
responsive to multiple inputs, as has recently been shown with engineered zinc finger
transcription factors.15 The greater targeting range of engineered TALE activators relative to
artificial zinc finger activators provides a substantial advantage for enabling synthetic
biology applications in which artificial circuits are designed to interface with endogenous
genes.
In this report, we have demonstrated that TALE activators should function efficiently to
regulate essentially any protein-coding or non-coding gene in human cells. This capability
provides a useful complement to cDNA overexpression or RNAi-based regulation strategies
for studying gene function and to previously described synthetic biology strategies for
regulating endogenous gene expression16–20. An important area for future investigation will
be the potential off-target effects of TALE activators in human cells (Supplementary
Discussion). Our successes with TALE activators in human cells should encourage use of
these proteins in other cell types and organisms. More importantly, our findings should
inspire the generation of other monomeric TAL effector-based fusion proteins that might be
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used to rationally alter expression and/or the epigenetic status of genes. Thus, our findings
should stimulate efforts to expand the repertoire of engineered TAL effector-based tools
available for research, synthetic biology, and therapeutic applications.
Methods
Selection of TALE-activator binding sites
For the human VEGF-A gene, target sites were chosen that fall within DNase I
hypersensitive sites previously described for 293 cells.13 For the NTF3 and miR-302/367
cluster genes, target sites were chosen within digital DNase I hypersensitive regions
identified from University of Washington ENCODE data using the UCSC genome browser
(http://genome.ucsc.edu/);21 we targeted these regions because they have been identified as
DNase I hypersensitive sites in multiple different cell types and we therefore reasoned that
these areas had a high probability of being in open chromatin.
Construction of TALE Activators
DNA fragments encoding TAL effector repeat arrays were generated using the Fast
Ligation-based Automatable High-throughput Assembly (FLASH) method as previously
described.12 These fragments were cloned using overhangs generated by digestion with
BsmBI restriction enzyme into expression vectors containing an EF1α promoter and the
Δ152 N-terminal and +95 C-terminal TALE-derived domains from the previously described
TALE activator NT-L+95.3 NF-KB p65 and VP64 activation domains were fused directly to
the C-terminal end of the +95 domain and all fusion proteins harbor a nuclear localization
signal.
Cell Culture and Transfection
Human Flp-In T-REx 293 cells and primary human BJ fibroblasts were maintained in
Advanced DMEM supplemented with 10% FBS, 1% penicillin-streptomycin and 1%
Glutamax (Life Technologies). Cells were transfected using either Lipofectamine LTX (Life
Technologies) or Nucleofection (Lonza) according to manufacturer’s instructions. Briefly,
for experiments targeting VEGF-A and NTF3 expression, 160,000 Flp-In T-REx 293 cells
were seeded in 24-well plates and transfected the following day with 300 ng of plasmid
encoding the TALE activator (except in the reduced-concentration VEGF-A experiments
(Figure 2d) in which 50 ng of plasmid encoding TALE activator and 250 ng of a control
plasmid expressing only the activation domain were transfected), 30 ng of pmaxGFP
plasmid (Lonza), 0.5 μl Plus Reagent and 1.65 μl Lipofectamine LTX. For the synergy
experiments with VEGF-A and NTF3, we transfected cells with 300 ng of TALE activator-
encoding plasmids (50 ng of each of six TALE activator-encoding plasmids for VEGF-A
and 60 ng of each of five TALE-activator-encoding plasmids for NTF3). For experiments
targeting miR-302/367 cluster expression, 5×105 BJ fibroblasts were Nucleofected with 10
μg of plasmid encoding TALE activator and 500 ng of pmaxGFP plasmid using the NHDF
kit (Lonza) and program U-023 on the Nucleofector 2b device. For the synergy experiment
with miR-302/367, we transfected cells with 10 μg of TALE activator-encoding plasmids (2
μg of each of five TALE activator-encoding plasmids).
ELISA Assays
Flp-In TREx 293 cells were transfected with plasmids encoding TALE activators targeted to
the human VEGF-A gene. All transfections were performed in triplicate. Cell media was
harvested 40 hours after transfection and secreted VEGF-A protein levels in the media were
assayed using a Human VEGF-A ELISA kit (R&D Systems). All samples were measured
according to the manufacturer’s instructions. Fold-activation values were calculated by
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dividing mean VEGF-A levels from media harvested from cells transfected with plasmids
expressing TALE activators by mean VEGF-A levels from cells transfected with plasmid
expressing only the VP64 or p65 activation domain.
Quantitative RT-PCR assays
To measure NTF3 mRNA levels, cells were harvested 2 days post-transfection and total
RNA was isolated using the TRIzol Plus RNA purification system (Ambion). RNA was
reverse transcribed using SuperScript III First-Strand Synthesis SuperMix and oligo-dT
primer (Life Technologies). qPCR was then performed using the following Taqman primer/
probe sets, as previously described3 except with the modification that the GAPDH probe
was labeled with HEX to allow for multiplexing - NTF3 forward primer: 5′-
GATAAACACTGGAACTCTCAGTGCAA-3′; NTF3 reverse primer: 5′-
GCCAGCCCACGAGTTTATTGT-3′; NTF3 taqman probe: 5′-/56-FAM/CAAACCTAC/
ZEN/GTCCGAGCACTGACTTCAGA/3IABkFQ/-3′; GAPDH forward primer: 5′-
CCATGTTCGTCATGGGTGTGA-3′; GAPDH reverse primer: 5′-
CATGGACTGTGGTCATGAGT-3′; GAPDH taqman probe: 5′-/5HEX/TCCTGCACC /
ZEN/ACCAACTGCTTAGCA/3IABkFQ/-3′. All TALE activator-encoding plasmids and
control plasmids were introduced into cells by Nucleofection in triplicate and qRT-PCR was
performed in triplicate on each sample.
To measure miR-302a transcript levels, cells were harvested 3 days post-transfection and
GFP-positive cells were isolated by flow cytometry. Total miRNA was isolated using the
mirVana miRNA Isolation Kit (Ambion). Reverse transcription and qPCR were performed
according to manufacturer’s instructions using Applied Biosystems Taqman microRNA
Assays (cat. #000529 for has-miR-302a and cat. #001006 for RNU48 control). Fold-
activation of miR-302a RNA transcripts was calculated by comparing transcript levels from
BJ fibroblasts transfected with plasmids encoding TALE activators to transcript levels from
BJ fibroblasts transfected with control plasmids expressing only the VP64 or p65 activation
domains and using the comparative CT (ΔΔCT) method. All TALE activators and controls
were introduced into cells by Nucleofection in triplicate and qRT-PCR for miR302a
transcript and small RNA control RNU48 were performed in triplicate on each sample.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Activities of 54 variable length TALE activators targeted to the endogenous human VEGF-
A gene. (a) Schematic depicting the human VEGF-A promoter region. The transcription
startpoint is indicated with a black arrow and previously published DNase I hypersensitive
regions13 are shown as grey bars. The DNase I hypersensitive region located between
positions +400 to +650 relative to the transcription start site has been expanded, with red
arrows indicating the locations and orientations of the 26 bp sites bound by the longest
length TALE-activator (harboring 24.5 TAL effector repeats) in each set. (b) Activation of
VEGF-A protein expression in 293 cells by 54 variable-length TALE activators. Cells were
transfected in triplicate with plasmids encoding each TALE-activator and then assayed as
described in Methods. Mean fold-activation values are shown with error bars representing
standard errors of the mean. All activators tested (except the 14.5-repeat activator from set
7) induced fold-activation of VEGF-A expression to a value significantly greater than 1, as
determined by a one-sided, paired t-test (P < 0.05).
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Activities of 16 TALE activators targeted to the endogenous human VEGF-A, miR-302/367
cluster, and NTF3 genes. For all three gene targets, experiments were performed in triplicate
with TALE activators harboring either the VP64 (green bars) or NF-KB p65 (blue bars)
activation domain. Error bars represent standard errors of the mean. (a) VEGF-A-targeted
TALE activators. Fold-activation values of VEGF-A protein were determined as described
in Methods. Asterisks indicate activators that induced fold-activation of VEGF-A
significantly greater than 1, as determined by a one-sided, paired t-test (P < 0.05). (b)
miR-302/367-targeted TALE activators. Fold-activation values of miR-302a transcript were
determined as described in Methods. Asterisks indicate activators that induced fold-
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activation of miR-302a transcript levels to a level significantly greater than 1 as determined
by a one-sided, paired t-test (P < 0.05). (c) NTF3-targeted TALE activators. Expression
levels of NTF3 mRNA relative to GAPDH mRNA are shown. Asterisks indicate activators
that induced significant elevation of NTF3 transcript levels relative to a control as
determined by a one-sided, paired t-test (P < 0.05). (d) Synergistic activation of VEGF-A.
Experiments were performed as in (a) except that the amount of DNA used for individual
TALE activators was six-fold lower. Asterisks indicate activators that induced fold-
activation of VEGF-A significantly greater than 1, as determined by a one-sided, paired t-
test (P < 0.05).
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